Vivian W Sung1, Holly E Richter, Pamela Moalli, Alison C Weidner, John N Nguyen, Ariana L Smith, Gena Dunivan, Beri Ridgeway, Diane Borello-France, Diane K Newman, Donna Mazloomdoost, Benjamin Carper, Marie G Gantz. 1. Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, Alpert Medical School of Brown University, Providence, Rhode Island; the Division of Urogynecology and Pelvic Reconstructive Surgery, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama; the Division of Urogynecology and Reconstructive Pelvic Surgery, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; the Division of Urogynecology, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina; the Division of Female Pelvic Medicine & Reconstructive Surgery, Department of Obstetrics & Gynecology, Kaiser Permanente, Downey, California; the Division of Urology, Department of Surgery, Perelman School of Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania; the Division of Urogynecology, Department of Obstetrics and Gynecology, University of New Mexico, Albuquerque, New Mexico; the Center for Urogynecology and Reconstructive Pelvic Surgery, Obstetrics, Gynecology and Women's Health Institute, Cleveland Clinic, Cleveland, Ohio; the Department of Physical Therapy, Rangos School of Health Sciences, Duquesne University, Pittsburgh, Pennsylvania; the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland; and Social, Statistical, & Environmental Sciences, RTI International, Research Triangle Park, North Carolina.
Abstract
OBJECTIVE: To evaluate characteristics associated with treatment failure 1 year after midurethral sling in women with mixed urinary incontinence. METHODS: Four hundred three women who participated in a randomized trial that compared midurethral sling and behavioral and pelvic floor muscle therapy (combined group) against midurethral sling alone for mixed incontinence with 1 year of follow-up data were eligible for this planned secondary analysis. Overall treatment failure was defined as meeting criteria for subjective failure, objective failure, or both. Subjective failure was defined as not meeting the minimal clinically important difference for improvement on the UDI (Urogenital Distress Inventory)-total score (26.1 points). Objective failure was not achieving 70% improvement on mean incontinence episodes of any type per day or having undergone any additional treatment for urinary symptoms at 12 months postoperative. Logistic regression models for treatment failure were constructed. Independent variables included site and treatment group, and clinical and demographic variables based on bivariate comparisons (P<.2). Treatment group interaction effects were evaluated. RESULTS: Previous overactive bladder medication use (unadjusted odds ratio [OR] 2.19, adjusted odds ratio [aOR] 1.89, 95% CI 1.10-3.25), detrusor overactivity on cystometrogram (OR 2.25, aOR 2.72, 95% CI 1.53-4.84), body mass index (OR 1.29, aOR 1.27, 95% CI 1.03-1.57), and Valsalva leak point pressure less than 60 cm H2O (OR 1.96, aOR 3.13, 95% CI 1.65-5.94) were associated with overall failure. Worse UDI urgency scores were associated with failure in the midurethral sling-alone group. Sling type (retropubic vs transobturator) was not associated with failure. CONCLUSION: Certain clinical and urodynamic variables are associated with treatment failure after midurethral sling among women with mixed urinary incontinence. Women with more severe urgency symptoms at baseline may benefit from perioperative behavioral and pelvic floor muscle therapy combined with midurethral sling. This information is helpful for counseling women with mixed incontinence who are considering surgery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01959347.
OBJECTIVE: To evaluate characteristics associated with treatment failure 1 year after midurethral sling in women with mixed urinary incontinence. METHODS: Four hundred three women who participated in a randomized trial that compared midurethral sling and behavioral and pelvic floor muscle therapy (combined group) against midurethral sling alone for mixed incontinence with 1 year of follow-up data were eligible for this planned secondary analysis. Overall treatment failure was defined as meeting criteria for subjective failure, objective failure, or both. Subjective failure was defined as not meeting the minimal clinically important difference for improvement on the UDI (Urogenital Distress Inventory)-total score (26.1 points). Objective failure was not achieving 70% improvement on mean incontinence episodes of any type per day or having undergone any additional treatment for urinary symptoms at 12 months postoperative. Logistic regression models for treatment failure were constructed. Independent variables included site and treatment group, and clinical and demographic variables based on bivariate comparisons (P<.2). Treatment group interaction effects were evaluated. RESULTS: Previous overactive bladder medication use (unadjusted odds ratio [OR] 2.19, adjusted odds ratio [aOR] 1.89, 95% CI 1.10-3.25), detrusor overactivity on cystometrogram (OR 2.25, aOR 2.72, 95% CI 1.53-4.84), body mass index (OR 1.29, aOR 1.27, 95% CI 1.03-1.57), and Valsalva leak point pressure less than 60 cm H2O (OR 1.96, aOR 3.13, 95% CI 1.65-5.94) were associated with overall failure. Worse UDI urgency scores were associated with failure in the midurethral sling-alone group. Sling type (retropubic vs transobturator) was not associated with failure. CONCLUSION: Certain clinical and urodynamic variables are associated with treatment failure after midurethral sling among women with mixed urinary incontinence. Women with more severe urgency symptoms at baseline may benefit from perioperative behavioral and pelvic floor muscle therapy combined with midurethral sling. This information is helpful for counseling women with mixed incontinence who are considering surgery. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01959347.
Authors: Holly E Richter; Michael E Albo; Halina M Zyczynski; Kimberly Kenton; Peggy A Norton; Larry T Sirls; Stephen R Kraus; Toby C Chai; Gary E Lemack; Kimberly J Dandreo; R Edward Varner; Shawn Menefee; Chiara Ghetti; Linda Brubaker; Ingrid Nygaard; Salil Khandwala; Thomas A Rozanski; Harry Johnson; Joseph Schaffer; Anne M Stoddard; Robert L Holley; Charles W Nager; Pamela Moalli; Elizabeth Mueller; Amy M Arisco; Marlene Corton; Sharon Tennstedt; T Debuene Chang; E Ann Gormley; Heather J Litman Journal: N Engl J Med Date: 2010-05-17 Impact factor: 91.245
Authors: P Abrams; K E Andersson; L Birder; L Brubaker; L Cardozo; C Chapple; A Cottenden; W Davila; D de Ridder; R Dmochowski; M Drake; C Dubeau; C Fry; P Hanno; J Hay Smith; S Herschorn; G Hosker; C Kelleher; H Koelbl; S Khoury; R Madoff; I Milsom; K Moore; D Newman; V Nitti; C Norton; I Nygaard; C Payne; A Smith; D Staskin; S Tekgul; J Thuroff; A Tubaro; D Vodusek; A Wein; J J Wyndaele Journal: Neurourol Urodyn Date: 2010 Impact factor: 2.696
Authors: Charles W Nager; Larry Sirls; Heather J Litman; Holly Richter; Ingrid Nygaard; Toby Chai; Stephen Kraus; Halina Zyczynski; Kim Kenton; Liyuan Huang; John Kusek; Gary Lemack Journal: J Urol Date: 2011-06-16 Impact factor: 7.450
Authors: Holly E Richter; Heather J Litman; Emily S Lukacz; Larry T Sirls; Leslie Rickey; Peggy Norton; Gary E Lemack; Stephen Kraus; Pamela Moalli; Mary Pat Fitzgerald; Kimberly J Dandreo; Liyuan Huang; John W Kusek Journal: Obstet Gynecol Date: 2011-04 Impact factor: 7.661
Authors: Charles W Nager; Linda Brubaker; Heather J Litman; Halina M Zyczynski; R Edward Varner; Cindy Amundsen; Larry T Sirls; Peggy A Norton; Amy M Arisco; Toby C Chai; Philippe Zimmern; Matthew D Barber; Kimberly J Dandreo; Shawn A Menefee; Kimberly Kenton; Jerry Lowder; Holly E Richter; Salil Khandwala; Ingrid Nygaard; Stephen R Kraus; Harry W Johnson; Gary E Lemack; Marina Mihova; Michael E Albo; Elizabeth Mueller; Gary Sutkin; Tracey S Wilson; Yvonne Hsu; Thomas A Rozanski; Leslie M Rickey; David Rahn; Sharon Tennstedt; John W Kusek; E Ann Gormley Journal: N Engl J Med Date: 2012-05-02 Impact factor: 91.245
Authors: Erin A Brennand; Selphee Tang; Colin Birch; Magnus Murphy; Sue Ross; Magali Robert Journal: Int Urogynecol J Date: 2016-09-29 Impact factor: 2.894
Authors: Matthew D Barber; Steven Kleeman; Mickey M Karram; Marie Fidela R Paraiso; Mark D Walters; Sandip Vasavada; Mark Ellerkmann Journal: Obstet Gynecol Date: 2008-03 Impact factor: 7.661
Authors: Vivian W Sung; Diane Borello-France; Gena Dunivan; Marie Gantz; Emily S Lukacz; Pamela Moalli; Diane K Newman; Holly E Richter; Beri Ridgeway; Ariana L Smith; Alison C Weidner; Susan Meikle Journal: Int Urogynecol J Date: 2016-06-10 Impact factor: 2.894
Authors: Heidi S Harvie; Vivian W Sung; Simon J Neuwahl; Amanda A Honeycutt; Isuzu Meyer; Christopher J Chermansky; Shawn Menefee; Whitney K Hendrickson; Gena C Dunivan; Donna Mazloomdoost; Sarah J Bass; Marie G Gantz Journal: Am J Obstet Gynecol Date: 2021-07-06 Impact factor: 8.661
Authors: Holly E Richter; Megan U Carnes; Yuko M Komesu; Emily S Lukacz; Lily Arya; Megan Bradley; Rebecca G Rogers; Vivian W Sung; Nazema Y Siddiqui; Benjamin Carper; Donna Mazloomdoost; Darryl Dinwiddie; Marie G Gantz Journal: Am J Obstet Gynecol Date: 2021-07-21 Impact factor: 10.693